Neutralization of tumor-derived soluble Glucocorticoid-Induced TNFR-Related Protein ligand increases NK cell anti-tumor reactivity

被引:45
作者
Baltz, Katrin M. [1 ]
Krusch, Matthias [1 ]
Baessler, Tina [1 ]
Schmiedel, Benjamin J. [1 ]
Bringmann, Anita [1 ,2 ]
Brossart, Peter [1 ,2 ]
Salih, Helmut R. [1 ]
机构
[1] Univ Tubingen, Dept Hematol & Oncol, D-72076 Tubingen, Germany
[2] Univ Bonn, Dept Hematol & Oncol, D-5300 Bonn, Germany
关键词
D O I
10.1182/blood-2008-03-143016
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
NK cell anti-tumor reactivity is governed by a balance of activating and inhibitory receptors including various TNF receptor (TNFR) family members. Here we report that human tumor cells release a soluble form of the TNF family member Glucocorticoid-Induced TNFR-Related Protein (GITR) ligand (sGITRL), which can be detected in cell culture supernatants. Tumor-derived sGITRL concentration-dependently reduced NK cell cytotoxicity and IFN-gamma production, which could be overcome by neutralization of sGITRL using a GITR-Ig fusion protein. Although sGITRL did not induce apoptosis in NK cells, it diminished nuclear localized ReIB, indicating that sGITRL negatively modulates NK cell NF-kappa B activity. Furthermore, we detected substantial levels of sGITRL in sera of patients with various malignancies, but not in healthy controls. Presence of sGITRL-containing patient serum in cocultures with tumor cells significantly reduced NK cell cytotoxicity and IFN-gamma production, which could again be restored by neutralization of sGITRL. The strong correlation of tumor incidence and elevated sGITRL levels indicates that sGITRL is released from cancers in vivo, leading to impaired NK cell immunosurveillance of human tumors. Our data suggest that determination of sGITRL levels might be implemented as a tumor marker in patients, and GITRL neutralization may be used to improve immunotherapeutic strategies relying on NK cell reactivity. (Blood. 2008; 112:3735-3743)
引用
收藏
页码:3735 / 3743
页数:9
相关论文
共 38 条
[31]   Soluble CD137 (4-1BB) ligand is released following leukocyte activation and is found in sera of patients with hematological malignancies [J].
Salih, HR ;
Schmetzer, HM ;
Burke, C ;
Starling, GC ;
Dunn, R ;
Pelka-Fleischer, R ;
Nuessler, V ;
Kiener, PA .
JOURNAL OF IMMUNOLOGY, 2001, 167 (07) :4059-4066
[32]   Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity [J].
Schneider, P ;
Holler, N ;
Bodmer, JL ;
Hahne, M ;
Frei, K ;
Fontana, A ;
Tschopp, J .
JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 187 (08) :1205-1213
[33]   The GITR-GITRL interaction: co-stimulation or contrasuppression of regulatory activity? [J].
Shevach, Ethan M. ;
Stephens, Geoffrey L. .
NATURE REVIEWS IMMUNOLOGY, 2006, 6 (08) :613-618
[34]   Stimulation of CD25+CD4+regulatory T cells through GITR breaks immunological self-tolerance [J].
Shimizu, J ;
Yamazaki, S ;
Takahashi, T ;
Ishida, Y ;
Sakaguchi, S .
NATURE IMMUNOLOGY, 2002, 3 (02) :135-142
[35]   Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells [J].
Turk, MJ ;
Guevara-Patiño, JA ;
Rizzuto, GA ;
Engelhorn, ME ;
Houghton, AN .
JOURNAL OF EXPERIMENTAL MEDICINE, 2004, 200 (06) :771-782
[36]   Proteolytic release of soluble UL16-binding protein 2 from tumor cells [J].
Waldhauer, I ;
Steinle, A .
CANCER RESEARCH, 2006, 66 (05) :2520-2526
[37]   Tnf/tnfr family members in costimulation of T cell responses [J].
Watts, TH .
ANNUAL REVIEW OF IMMUNOLOGY, 2005, 23 :23-68
[38]   Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer [J].
Wu, JD ;
Higgins, LM ;
Steinle, A ;
Cosman, D ;
Haugk, K ;
Plymate, SR .
JOURNAL OF CLINICAL INVESTIGATION, 2004, 114 (04) :560-568